As contrast market founders, radiopharmaceuticals show promise

04/30/2013 | DOTMed.com

The decline in the U.S. contrast agents market is likely to last until 2017, according to this article. Companies expected to be affected include GE Healthcare, Mallinckrodt and Lantheus Medical Imaging. However, analyst Ravindra Sharma said the radiopharmaceuticals sector is a promising area, and the CMS decision on Amyvid will be watched closely. Another trend in the field is advancement not just in the chemical composition of contrast agents but in how they are administered, such as in the use of software to allow for integration of injectors, PACS and imaging devices.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Counsel Commercial
RAI Services Company
Winston Salem, NC
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA